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BY-NC-ND license (http://creativecomAbstract Background/Purpose: Streptococcus pneumoniae is one of the most common path-
ogens to cause mucosal and invasive infection in humans. Resistance to fluoroquinolones (FQ)
is associated with clinical failure when treating pneumococcal diseases and increase of mortal-
ity.
Methods: We collected clinical isolates of S. pneumoniae from January 2011 to July 2015 at
Chang Gung Memorial Hospital, Taoyuan, Taiwan. Susceptibility to FQ was examined by disk
diffusion method. Levofloxacin or moxifloxacin-nonsusceptible S. pneumoniae isolates were
analyzed by serotyping, multilocus sequence typing, and sequencing of the quinolone
resistance-determining regions (QRDRs) of gyrA, gyrB, parC, and parE.
Results: During the study period, 42 FQ-nonsusceptible pneumococcal isolates were identified.
The rate increased from 1.6% of total pneumococcal isolates (2 of 127) in 2011 to 4.6% (13 of
283) in 2014, then decreased to 1.5% (3 of 202) in the first half of 2015. These isolates belonged
to 13 serotypes, and serotype 14 (12 of 42, 33.3%) was the most prevalent. Most of the isolates
belonged to international clones or their variants. After QRDR analysis, there were 19 isolates
in five clusters that shared both the same sequence type and QRDR mutation.
Conclusions: FQ resistance initially emerged in either vaccine or nonvaccine serotypes. The
majority of isolates were international clones or related variants, suggesting that resistancen Chiu, Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial
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Fluoroquinolones (FQs), especially so-called respiratory
FQs (levofloxacin, gatifloxacin, and moxifloxacin), have
good in vitro activity against Streptococcus pneumoniae,
one of the most important pathogens for bacterial pneu-
monia, meningitis, acute otitis media, and septicemia in
humans. Resistance to FQ has been reported since the mid-
1990s in North America and Europe in clonally distinct
strains.1,2 S. pneumoniae with FQ resistance has also been
reported in Asia and Africa.3,4 Further clinical reports sug-
gest that resistance to FQ is associated with clinical failure
when treating pneumococcal infections using these
agents.5,6
The antimicrobial effects of FQ originate from the inhi-
bition of bacterial DNA gyrase and topoisomerase IV. The
two subunits of DNA gyrase, GyrA and GyrB, are encoded by
gyrA and gyrB genes, whereas the two subunit of topo-
isomerase, ParC and ParE, are encoded by parC and parE.
Mutations in the quinolone resistance-determining regions
(QRDRs) of gyrA, gyrB, parC, and parE are closely related to
FQ resistance in S. pneumoniae. Efflux pumps are also
documented to be related to FQ resistance. However, the
influence of efflux pumps to moxifloxacin and levofloxacin
resistance is relatively less, compared with the QRDR
mutations.7
The pneumococcal seven-valent conjugate vaccine
(PCV7) has been introduced to Taiwan to prevent pneu-
mococcal infection since 2005. Introduction of pneumo-
coccal 13-valent conjugate vaccine (PCV13) for use in 2011
further reduced the infections caused by non-PCV7 sero-
types.8 In this article we report the serotypes, sequence
types, and antimicrobial susceptibility of FQ-
nonsusceptible S. pneumoniae isolates collected from a
medical center in Taiwan in the pneumococcal conjugate
vaccine era. The resistance mechanisms of FQ-
nonsusceptibility were studied by sequencing the QRDR of
gyrA, gyrB, parC, and parE genes.Methods
Bacterial isolates
Clinical isolates of S. pneumoniae were prospectively
collected from January 2011 to July 2015. If multiple iso-
lates were identified from the same patients, only the first
isolate was retained for further investigation. All isolates
were cultured and identified with standard methods in the
Clinical Microbiology Laboratory at Chang Gung Memorial
Hospital (CGMH), Taoyuan, Taiwan.hen H-H, et al., Fluoroquinolone-n
ate vaccine era, Journal of MicAntimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) of penicillin and
ceftriaxone were analyzed by E-test (AB Biodisk, Solna,
Sweden). Susceptibilities to levofloxacin and moxifloxacin
were examined by a standard disc-diffusion method. The
results were interpreted according to the suggestions of the
Clinical Laboratory Standards Institute.9,10
Serotyping and genotyping
The serotypes of pneumococcal isolates were determined
by using commercialized antisera (Statens Serum Institut,
Copenhagen, Denmark) and polymerase chain reaction
methods, as previously described.11e13 Multilocus sequence
typing was further determined by the polymerase chain
reaction sequencing of a set of pneumococcal house-
keeping genes (aroE, gdh, gki, recP, spi, xpt, and ddl ) with
the use of published primers.14 The sequence data were
compared to the multilocus sequence typing database
maintained in the public domain (http://spneumoniae.
mlst.net). New alleles and allelic profiles were submitted
to the database curator for the assignment of sequence
type (ST) numbers. For isolates showing fluoroquinolone
resistance, the QRDRs of the gyrA, gyrB, parC, and parE
genes were analyzed by a published method.15
Statistical analysis
Poisson test was applied to analyze the isolation rate of FQ-
nonsusceptible S. pneumoniae between years. A p val-
ue < 0.05 indicated a significant difference between
different years.
Results
From 2011 to the first 6 months of 2015, 1281 S. pneumo-
niae isolates were collected from CGMH, and 42 levo-
floxacin or moxifloxacin-nonsusceptible isolates were
identified. From 2011 to 2015, the number of FQ-
nonsusceptible isolates increased in CGMH. We recorded a
2.9-fold increase in rate from 1.6% (2 of 127) in 2011, 3.6%
(13 of 359) in 2012, and 3.5% (11 of 310) in 2013, to 4.6% (13
of 283) in 2014, but it decreased to 1.5% (3 of 202) in the
first 6 months of 2015 (Figure 1). The decrease in 2015
reached statistical significance, when compared to data in
either 2014 (p Z 0.012) or 2011e2014 (p Z 0.043). The
mean age of these patients was 58 years with a median of
77 years (range, 3e100 years).
The characteristics of the 42 levofloxacin ormoxifloxacin-
nonsusceptible S. pneumoniae isolates from CGMH areonsusceptible Streptococcus pneumoniae isolates from a medical
robiology, Immunology and Infection (2016), http://dx.doi.org/
Figure 1. Incidence of fluoroquinolone-nonsusceptible
Streptococcus pneumoniae isolates among different serotypes
from January 2011 to July 2015 in Chang Gung Memorial Hos-
pital. The nationwide catch-up program was launched in 2013
(white arrow) and national immunization program with a three-
dose schedule in 2015 (black arrow). The decrease in 2015
reached statistical significance, comparing to either 2014
(p Z 0.012) or 2011e2014 (p Z 0.043).
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Figure 2. The majority of isolates (36 of 42, 85.76%) were
from respiratory tract secretions, including six isolates from
patients with acute sinusitis. Only one of the six isolates from
sinusitis was PCV13 serotype (Serotypes 3, 15A, 15B, and 34).
Six of the 42 FQ-nonsusceptible S. pneumoniae isolates were
cultured from blood. All of these six patients with blood-
stream infection were adults aged 49e100 years, and four of
them were older than 65 years. Five of the six blood isolates
were PCV13 serotypes and the most prevalent was serotype
14 (4 of 6, 66.6%). Seven of the 42 FQ-nonsusceptible S.
pneumoniae isolates were cultured from pediatric patients
(age 3e16 years) and all of the pediatric isolates were
derived from respiratory secretions. Four of the six pediatric
isolates were pus drained form acute sinusitis, and none of
them were PCV13 serotypes. Two were serotype 15A and
others were serotype 15B. Other pediatric isolates belonged
to PCV13 serotypes (serotypes 19F and 23F). Three FQ-
nonsusceptible isolates were collected in the first 6 months
of 2015, all from sputum of adult patients. The serotypes of
the three isolates were 14, 15B, and 23F.
The following 13 serotypes were found among the FQ-
nonsusceptible isolates: 14 (n Z 12, 33.3%), 15B (n Z 6,
14.2%), 23F (n Z 7, 16.6%), 19F (n Z 4, 9.5%), 23A (n Z 3,
7.1%), 15A (nZ 3, 7.1%), 3 (nZ 1, 2.4%), 6A (nZ 1, 2.4%),
9V (n Z 1, 2.4%), 11A (n Z 1, 2.4%), 13 (n Z 1, 2.4%), 19A
(n Z 1, 2.4%), and 34 (n Z 1, 2.4%). The PCV13 serotypes
were dominant in these isolates (n Z 27, 64.3%).
Alterations in GyrA were found in 41 isolates, mostly in
S81 (n Z 39, 92.8%), and 14 (35.8%) of them had another
alteration in S114. Another GyrA alteration found in two
other isolates was E85. Alterations in ParC were also found
frequently (nZ 35, 83.3%). All of these isolates had S79
alteration, and two of them were combined with both S52
and N91 alterations. In ParE the most frequent alteration
was in D435 (n Z 16, 38.1%); others were A326 (n Z 7,
16.7%), P454 (n Z 1, 2.4%), and R447 (n Z 1, 2.4%). OnlyPlease cite this article in press as: Chen H-H, et al., Fluoroquinolone-n
center in the pneumococcal conjugate vaccine era, Journal of Mic
10.1016/j.jmii.2016.05.003one isolate had both D435 and A326 alterations. GyrB al-
terations were not identified among the FQ-nonsusceptible
S. pneumoniae isolates in CGMH. Among the 42 isolates, a
combination of two or more alterations in QRDR was found
in 41 isolates, including GyrA plus ParC (nZ 17, 40.4%), and
Gyr A plus ParE (nZ 6, 14.3%). Eight isolates (19%) showed
alteration in all GyrA, ParC, and ParE. One isolate had ParE
alteration only.
We identified 19 genotypes among the 42 FQ-
nonsusceptible S. pneumoniae isolates. Most (n Z 40,
95.2%) were international clones or related variants. The
most prevalent genotype was ST876 (n Z 10, 23.8%), a
single locus variant of Netherlands15B-37, and all were
serotype 14. The second largest genotype was ST83 (nZ 5,
11.9%), a single locus variant of Spain23F-1, all were sero-
type 15B. Other genotypes contained three isolates were
ST63 (Sweden15A-25), all 15A; ST242 (Taiwan23F-15), and
ST81 (Spain23F-1). Among most of these isolates with similar
genotype, we found identical QRDR amino acid alterations.
In all ST876 isolates we found S81W with S114G in GyrA and
S79F in ParC. D435N was also found in nine of the 10 ST876
isolates. In all ST7128 isolates, we identified S81W in GyrA
and S79F in ParC. In all ST81 isolates there were S81W in
GyrA, S79F in ParC, and A326V in ParE. Identical multiple
QRDR alteration was found in two ST81 (serotype 15B) iso-
lates; both were cultured from pediatric patients with
acute sinusitis. These alterations included S81Y with S114G
in GyrA; S79I, S52G, and N91D in ParC; and A326V in ParE.
Only seven (16.7%) isolates among the 42 FQ-
nonsusceptible S. pneumoniae isolates from CGMH were
susceptible to ceftriaxone (MIC  0.5 mg/mL). By contrast,
there were 35 (83.3%) penicillin-susceptible (MIC  2 mg/
mL) isolates found. All the penicillin-nonsusceptible iso-
lates were considered multidrug-resistant because they
were also nonsusceptible to ceftriaxone.Discussion
According to a previous survey, the overall resistance rates
to respiratory fluoroquinolones in pneumococci remained
low in most Asian countries, while levofloxacin and moxi-
floxacin resistance was more frequent in Korea and
Taiwan.16,17 A study from northern Taiwan revealed a sig-
nificant increase of the prevalence of levofloxacin-
nonsusceptible S. pneumoniae from 1.2% in 2001 to 4.2%
in 2007.18 The trend was also found in our study from 2011
to 2014 and ceased in the first half of 2015. Prescription of
antibiotic for respiratory tract infection was closely related
to the development of bacterial resistance to antibi-
otics.19,20 The use of FQ in the treatment of tuberculosis
was proposed in previous studies to increase the potential
for the spread of levofloxacin-nonsusceptible pneumo-
cocci.21 However, levofloxacin treatment for tuberculosis
was excluded from the benefit package of Taiwan’s Na-
tional Health Insurance since 2007. Another important
event that may promote the prescription of respiratory FQ
was the modification of the management guideline on
community-acquired pneumonia, in which respiratory FQ
was recommended to be the first-line outpatient treatment
for those with comorbidities.22 The record from our anti-
biotic stewardship program also showed an increase in theonsusceptible Streptococcus pneumoniae isolates from a medical
robiology, Immunology and Infection (2016), http://dx.doi.org/
Table 1 The characteristics of the 42 levofloxacin or moxifloxacin-nonsusceptible Streptococcus pneumoniae isolates
Related international clone Sex Age (y) Source Sequence type Serotype QRDRs MIC (mg/
mL)
GyrA GyrB ParC ParE Pen Cro
Netherlands15B-37 F 91 Blood 876 (SLV199) 14 S81W
S114G
d S79F D435N 0.5 1
M 73 Respiratory 876 (SLV199) 14 S81W
S114G
d S79F D435N 1 1
F 79 Respiratory 876 (SLV199) 14 S81W
S114G
d S79F D435N 1 1
M 83 Respiratory 876 (SLV199) 14 S81W
S114G
d S79F D435N 1 1
M 60 Respiratory 876 (SLV199) 14 S81W
S114G
d S79F D435N 1 1
M 24 Respiratory 876 (SLV199) 14 S81W
S114G
d S79F D435N 2 1
M 49 Respiratory 876 (SLV199) 14 S81W
S114G
d S79F D435N 2 1
M 73 Respiratory 876 (SLV199) 14 S81W
S114G
d S79F D435N 2 2
F 100 Blood 876 (SLV199) 14 S81W
S114G
d S79F D435N 4 1
F 94 Respiratory 876 (SLV199) 14 S81W
S114G
d S79F d 1 1
F 49 Blood 5749 (SLV199) 14 S81W
S114G
d S79F D435N 1 1
M 60 Blood 9635 (SLV199) 14 S81W
S114G
d d D435N 2 2
Spain23F-1 M 72 Respiratory 81 23F S81F d S79F A326V 1 1
M 86 Respiratory 81 19F S81F d S79F A326V 1 2
M 86 Respiratory 81 19F S81F d S79F A326V 2 2
M 4 Pus 83 (SLV81) 15B S81Y
S114G
d S52G
S79I
N91D
A326V 4 2
M 5 Pus 83 (SLV81) 15B S81Y
S114G
d S52G
S79I
N91D
A326V 4 2
F 72 Respiratory 83 (SLV81) 15B S81F d d A326V
D435N
2 2
F 48 Respiratory 83 (SLV81) 15B E85K d d D435N 2 1
M 30 Respiratory 83 (SLV81) 15B S81F d S79Y d 4 2
M 81 Respiratory 10079 15B S81F d S79F A326V 2 0.5
Taiwan23F-15 M 12 Respiratory 242 23F S81F d S79Y R447C 0.25 0.125
M 70 Respiratory 242 23F S81F d d D435N 2 2
F 7 Respiratory 242 23F S81Y d S79F d 1 1
M 75 Pus 9625 (SLV242) 3 S81F d d D435N 1 1
M 71 Blood 7128 (DLV242) 23F S81F d S79F d 2 2
M 81 Respiratory 7128 (DLV242) 23F S81F d S79F d 8 8
M 75 Respiratory 7128 (DLV242) 23F S81F d S79F D435N 8 4
Taiwan19F-14 F 16 Respiratory 236 19F S81F d d D435N 2 1
M 71 Respiratory 9998 (SLV236) 19F S81F d S79F d 2 2
M 67 Respiratory 320 (DLV236) 19A S81F d S79Y d 4 2
Colombia23F-26 M 66 Respiratory 338 23A E85K d S79F d 0.25 0.25
M 90 Respiratory 338 23A S81F
P33H
d S79F d 0.5 0.25
M 85 Blood 8080 (SLV338) 23A S81F d S79F d 0.5 0.5
Spain9V-3 F 40 Respiratory 166 (SLV156) 13 S81F d S79Y d 2 2
M 57 Respiratory 166 (SLV156) 11A S81F d S79F d 2 2
M 76 Respiratory 166 (SLV156) 9V S81F
S114G
d S79Y d 2 2
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Table 1 (continued )
Related international clone Sex Age (y) Source Sequence type Serotype QRDRs MIC (mg/
mL)
GyrA GyrB ParC ParE Pen Cro
Sweden15A-25 M 3 Pus 63 15A S81F d S79F d 1 1
M 7 Pus 63 15A S81F d S79F d 2 1
M 67 Respiratory 63 15A S81F d S79F d 2 1
M 33 Pus 6823 34 d d d P454S 0.01 0.01
M 71 Respiratory 855 6A S81F d S79F d 0.5 0.5
CroZ ceftriaxone; MICZminimum inhibitory concentration; PenZ penicillin; QRDRZ quinolone resistance-determining region; single
locus variant (SLV).
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+ MODELconsumption of FQ, especially in 2015 when the annual
consumption was significantly higher than the average
amount from 2010 to 2014 (data not shown). The increasing
trend of FQ prescription in Taiwan was described in a
retrospective study.23 An appropriate antibiotic steward-
ship program that promotes the judicious use of FQ from
the treatment of respiratory tract infections should be
emphasized to stop the increasing trend of FQ resistance in
respiratory pathogens.
Clinical evidence indicates that use of PCV7 had
changed the course of an upward trend in fluoroquinolone
resistance.24e26 PCV7 was first available in 2005 in Taiwan,
followed by PCV10 in 2010 and PCV13 in 2011.8 The PCV7
vaccination rate among children aged 5 years or younger
reached 45.5% in 2010. In 2013, a national catch-up im-
munization program providing one dose of PCV13 for
children aged 2e5 years was launched, which raised
the proportion of PCV13 immunization with the recom-
mended schedules rapidly from 31.9% to 64.2% in 2013.27Figure 2. Distribution of serotypes among the 42 fluo-
roquinolone-nonsusceptible Streptococcus pneumoniae isolates.
Please cite this article in press as: Chen H-H, et al., Fluoroquinolone-n
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10.1016/j.jmii.2016.05.003In our observation, the prevalence of FQ-nonsusceptible
S. pneumoniae isolates belonging to PCV13 serotypes
decreased from 3.2% in 2013, 2.1% in 2014, to 0.7% in
2015. The proportion of PCV13 serotypes among FQ-
nonsusceptible S. pneumoniae isolates also decreased
from 90.9% in 2013 to 46.1% in 2014 and 66.7% in 2015. In
2015, the national immunization program of PCV13 was
promoted to offer a three-dose schedule. The promotion,
which was documented to provide protection as the
standard schedule, appears to be related to the decrease
of FQ-nonsusceptible rate we observed in the first half of
2015.28 The PCV13 serotypes were reported to be the
major serotypes of FQ-nonsusceptible isolates in previous
studies.24,25 The observation suggested that the use of
PCV13 contributed to the reduction of FQ-nonsusceptible
pneumococcal infection.24,25 Since the proportion of FQ-
nonsusceptible S. pneumoniae isolates with PCV13 sero-
types remains high, the nationwide vaccination policy is
important in minimizing the emergence of FQ resistance in
Taiwan.
Despite the decrease of PCV13 serotypes, the preva-
lence of FQ-nonsusceptible S. pneumoniae in CGMH has
still been increasing from 2011 to 2014. The proportion of
the non-PCV13 serotypes among FQ-nonsusceptible iso-
lates has increased. A prospective survey in Hong Kong 2
years after PCV13 use demonstrated that serogroup 15 was
the most common among nasopharyngeal carriage isolates
in children aged 5 years or younger, probably due to
expansion of preexisting clones.29 The increasing propor-
tion of serogroup 15 was also reported in a cross-sectional
survey of children aged 3e40 months within a French
population with 82.7% of PCV13 coverage rate.24Among
our 42 S. pneumoniae isolates, all the isolates from pa-
tients aged 5 years or younger and those from pus of
sinusitis belonged to serogroup 15. Moreover, two isolates
of serotype 15B with identical sequence type and QRDR
alterations were identified, suggesting an important role
of serogroup 15 in PCV13 era. Close monitoring is
necessary.
Evidence of clonal dissemination attributable to fluo-
roquinolone resistance has been reported in Hong Kong,
Spain, and USA.25,30e32 Variation of QRDR was demon-
strated in previous studies from USA and a cluster of iso-
lates that shared the same sequence was found to have
identical QRDR mutation.25,32 Moreover, all isolates in the
cluster were from one state. This was considered strongonsusceptible Streptococcus pneumoniae isolates from a medical
robiology, Immunology and Infection (2016), http://dx.doi.org/
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for levofloxacin-nonsusceptible S. pneumoniae was carried
out from 2004 to 2006 in CGMH and another medical cen-
ter.16 The international clones or related variants were
identified in the study but the QRDR mutations were het-
erogeneous among isolates with a similar genotype, indi-
cating that part of the dissemination may originate from
independent selection. In our study, most of the FQ-
nonsusceptible S. pneumoniae isolates belonged to inter-
national clones or their variants. The QRDR analysis found
that many isolates, cultured in different years from pa-
tients with different age, sex, and specimens, shared both
the same sequence type and identical QRDR mutation. This
included two multidrug-resistant isolates of ST83 that had
eight different amino acid alterations among three QRDRs.
Since our isolates were cultured from a single medical
institution, the homogeneity of QRDR mutations indicated a
growing burden of clonal spread among FQ-nonsusceptible
strains.
In conclusion, our observations demonstrate a rising
trend of FQ resistance among S. pneumoniae, which
seemingly ceased after the introduction of PCV13 into the
national immunization program. We also found the transi-
tion of the dominance by PCV13 serotypes to that by non-
PCV13 serotypes. Due to the homogeneity of QRDR in
different isolates, clonal spreading among FQ-
nonsusceptible strains was proposed. Strategies including
antimicrobial stewardship, nationwide vaccination policy,
and continuous surveillance are necessary to reduce the
dissemination of FQ-nonsusceptible S. pneumoniae.
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